Acral melanoma (AM), localized to the palms, soles, and nail units, is a unique melanoma subtype less associated with UV radiation. Few studies have evaluated AM risk factors in a population of US veterans. To identify AM risk factors in US veterans. Nested case-control study (2000-2024) in the Veterans Affairs (VA) health care system. Individuals with AM were identified using the VA Cancer Registry and a validated natural language processing pipeline applied to pathology reports. Each AM case was matched to 4 nonacral cutaneous melanoma (CM) controls and 4 controls with no melanoma diagnoses at any time by diagnosis year and outpatient visit frequency. Controls with acral, mucosal, or ocular melanoma diagnoses at any time were excluded. Participants were veterans with histologically confirmed AM, nonacral CM controls, and controls with no melanoma diagnoses at any time. Age, sex, race and ethnicity, rurality, region, military branch, comorbidities (National Cancer Institute Comorbidity Index), smoking status, unhealthy alcohol use as measured by the Alcohol Use Disorders Identification Test-Consumption, body mass index, Agent Orange exposure (AOE), prior photosensitizing medications, nevi, keratinocyte carcinoma (KC), actinic keratosis (AK), and number of dermatology visits in the 2 years before diagnosis. Adjusted odds ratios (AORs) comparing AM with controls using conditional logistic regression. Secondary outcomes included analyses limited to Vietnam Era veterans and AM localized to palmoplantar and subungual sites. In total, 1292 individuals with AM (median age, 70.13 [IQR, 61.87-78.66] years; 1215 [94.0%] male) were matched to 5168 controls without melanoma (median age, 73.97 [IQR, 65.53-82.08] years; 5044 [97.6%] male), and 1286 individuals with AM (median age, 70.13 [IQR, 61.97-78.67] years; 1210 [94.1%] male) were matched to 5144 CM controls (median age, 74.58 [IQR, 66.86-82.05] years; 5068 [98.5%] male); 6 individuals with AM were excluded from AM vs CM analyses due to lack of matches. AOE was significantly associated with higher odds of AM vs CM (AOR, 1.31; 95% CI, 1.06-1.62) and vs controls without melanoma (AOR, 1.27; 95% CI, 1.04-1.56). Current smoking was associated with lower odds of AM (vs CM: AOR, 0.65; 95% CI, 0.52-0.81; vs controls without melanoma: AOR, 0.50; 95% CI, 0.40-0.62). Prior KC and AK were associated with higher odds vs controls without melanoma but lower odds vs CM. Prior nevus was associated with higher odds of AM vs controls without melanoma. Results of this study suggest that several factors were associated with AM in veterans and a need for continued investigation of AM as a distinct entity from CM and may inform future evaluations of the associations between AOE and AM in veteran populations.

Mucosal melanoma (MM) is an aggressive and rare subtype of melanoma, and it is associated with poor prognosis. Surgical resection remains the mainstay of the treatment for localized disease, and different from cutaneous melanoma, the impact of adjuvant therapy has not been clearly established. We retrospectively analyzed patients with surgically resected MM from the MD Anderson Cancer Center melanoma database from January 2000 to December 2019. The univariate log-rank test and multivariate Cox regression model were used to analyze the impact of adjuvant therapy on overall survival (OS) and relapse-free survival. A total of 246 patients with localized or locally advanced MM who underwent surgical resection were included. The median OS for all patients was 4.8 years [95% confidence interval (CI), 3.6-6], with median OS for the 125 patients who received adjuvant systemic therapy was 5.7 years (95% CI, 4.0-10.2) and 4.0 years (95% CI, 2.8-6.6) for the 121 patients who had only surgery or surgery plus radiation in the subanalysis, chemotherapy was associated with a longer OS (7.3 years; 95% CI, 4.4-NA) compared to immunotherapy (5.5 years; 95% CI, 2.8-NA). Cox regression analysis demonstrated lymph node involvement, Breslow thickness, and use of adjuvant systemic therapy were considered independent factors for OS. Adjuvant systemic therapy was associated with a significant survival benefit in patients with resected MM (HR 0.53; 95% CI, 0.34-0.82; P = 0.004). However, due to the retrospective nature of the study, prospective clinical trials are warranted to determine the optimal adjuvant treatment strategy for this patient population.

Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma risk in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy have shown great promise. Other advances, particularly through the exploration of novel and combination therapies is a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.

Background: Mucosal malignant melanoma (MMM) is a rare and aggressive malignancy with a dismal prognosis. While the Systemic Immune-Inflammation Index (SII) has emerged as a prognostic marker in various solid tumors, its specific value in MMM remains undefined. This study investigated the association between pretreatment SII and overall survival (OS) in patients with MMM. Methods: We retrospectively analyzed 106 adults with histologically confirmed MMM treated at six oncology centers in Turkey between 2005 and 2025. The baseline SII was calculated as platelet × neutrophil/lymphocyte counts obtained before definitive treatment. A receiver operating characteristic (ROC) analysis identified an optimal SII cutoff of 776 for overall survival (OS), defining low (<776) and high (≥776) SII groups. Results: Gastrointestinal and head and neck mucosa were the most frequent primary sites, and one-third of patients presented with metastatic disease. The median OS for the entire cohort was 23.3 months. Patients with a high versus low SII had a shorter OS (16.2 vs. 35.2 months; HR 2.71, 95% CI 1.67–4.40; p < 0.001). In multivariable analysis, a high SII (HR 1.88, 95% CI 1.12–3.14; p = 0.016), gastrointestinal primary site (HR 1.99, 95% CI 1.23–3.23; p = 0.005), and metastatic disease at diagnosis (HR 4.01, 95% CI 2.32–6.94; p < 0.001) independently predicted a worse OS. Conclusions: The SII is a novel, independent prognostic biomarker in MMM. Elevated pretreatment SII correlates with aggressive clinicopathologic features and inferior survival. As a readily accessible and cost-effective marker, SII may facilitate improved risk stratification in routine clinical practice for MMM patients.

Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma.

While mucosal-based melanomas of the head and neck region are uncommon lesions, when they do arise, they usually exhibit a highly aggressive clinical course. Experience with these tumors is, limited; as such, well worked out treatment protocols for the treat- ment of such lesions are in short supply. It appears as though mucosal melanomas (MuMs) develop more frequently in the nasal cavity and paranasal sinus region, and less often in the oral cavity. The incidence of nodal metastasis seems to be significantly lower in si- nonasal MuMs than it is in MuMs of the oral cavity; this observation may be useful in evalu- ating whether a neck dissection is necessary to determine the location of the primary MuM.

Sinonasal cancers (SNC) are heterogeneous diseases with different clinical behavior. We aimed to identify prognostic factors in non-metastatic (M0)-SNC. Electronic health records from M0-SNC patients treated with definitive surgery ± postoperative radiotherapy or chemoradiotherapy at two tertiary institutions were reviewed. p16 staining was performed in the squamous cell carcinoma (SCC) subset. Multivariable analysis (MVA) calculated the adjusted hazard ratio (aHR) for histology type (SCC as the comparator), T/N categories, and primary treatment modality for the risk of locoregional failure (LRF), distant metastasis (DM), and deaths. A total of 376 patients were eligible including 209 (56%) SCC (p16+: 35; p16-/untested: 157), 42 (11%) adenocarcinoma, 35 (9%) sinonasal undifferentiated carcinoma or sinonasal neuroendocrine tumors (SNUC/SNEC), 33 (9%) mucosal melanoma (MM), 30 (8%) esthesioneuroblastoma (ES), and 27 (7%) adenoid cystic carcinoma (ACC). MVA identified MM histology (aHR 2.03, 95% CI 21.23-3.33), older age (aHR 1.02; 95% CI: 1.00-1.03), T3-4 tumor (aHR 5.08, 95% CI 2.77-9.30), and nodal involvement (aHR: 2.15, 95% CI 1.46-3.16) carried higher mortality risk (all p < 0.05); MM (aHR 10.14, 95% CI 4.90-21.01), ACC (aHR 2.97, 95% CI 1.27-6.96), and SNUC/SNEC (aHR 6.80, 95% CI 3.30-14.01) histologies and T3-4 categories (vs. T1-2, HR 4.79, 95% CI 1.53-14.95) had higher DM risk; T3-4 (aHR 2.33, 95% CI 1.37-3.97) and nodal involvement (aHR 1.70, 95% CI 1.11-2.60) conveyed higher LRF risk while SNUC/SNEC histologies had a lower LRF risk (aHR 0.51, 95% CI 0.26-3.33). Different SNC histology types exhibit distinct patterns of relapse and survival, highlighting the need for different management strategies.

PurposeSinonasal mucosal melanoma (SNMM) accounts for approximately 4-8% of sinonasal malignancies. SNMM frequently originates in the nasal cavity, causing nonspecific nasal symptoms that inevitably delay diagnosis. Left untreated, the tumor may extend into the orbit.Case DescriptionHerein, the authors describe two patients presenting with compressive optic neuropathy and were found to have advanced SNMM involving the orbit. Both patients presented with vision loss, decreased color vision, proptosis, conjunctival chemosis, and restricted extraocular movements. One patient was found to have a relative afferent pupillary defect. Neither patient was a surgical candidate, and both received palliative radiotherapy and immunotherapy.ConclusionsThese cases and literature review demonstrate the potential for the disease to initially manifest with orbital extension and ocular symptoms. Ophthalmologists can play a crucial role in the early detection of SNMM, which may improve outcomes, given the challenges of SNMM treatment.

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced malignant melanoma. This study examined the real-world efficacy of dacarbazine in patients who had previously received pembrolizumab, based on the hypothesis that prior ICI treatment enhances the therapeutic response to subsequent chemotherapy. This retrospective study included 71 patients with histologically confirmed malignant melanoma treated at Kyungpook National University Chilgok Hospital (Daegu, Korea) between 2011 and 2023. The patients received dacarbazine for unresectable stage IIIC, IIID, or IV melanoma (American Joint Committee on Cancer, 8th edition). Among the 71 patients, the median patient age was 64 years (range, 25-89 years). When categorized by melanoma subtype, 18 patients (25.4%) had acral melanoma, 40 (56.3%) had cutaneous melanoma, and 13 (18.3%) had mucosal melanoma. Sixteen of the dacarbazine-treated patients had not received pembrolizumab previously (DTI-only group), while 55 had (pem-DTI group). The median progression-free survival was 2.3 months in the DTI-only group and 3.9 months in the pem-DTI group (hazard ratio [HR], 0.246; 95% confidence interval [CI], 0.106-0.576; p=0.001). The median overall survival was 6.8 months in the DTI-only group and 19.0 months in the pem-DTI group (HR, 0.198; 95% CI, 0.068-0.574; p=0.003). The duration of response (DoR) was 4.64 months in the DTI group and 8.11 months in the pem-DTI group. This study demonstrated that the DoR to dacarbazine was prolonged following ICI therapy (4.64 months vs. 8.11 months). This indicates that prior ICI treatment may enhance tumor sensitivity to chemotherapy, making dacarbazine a viable option for treating refractory, relapsed, or progressive melanoma.

A Case of Long-term Survival of a Patient with Eustachian Tube Mucosal Melanoma

Background/Objectives: Neoadjuvant and perioperative treatment regimens for melanoma have demonstrated significantly longer event-free survival (EFS) compared with adjuvant therapy in the NADINA and SWOG S1801 trials. While these studies yielded promising results, real-world effectiveness and safety remain to be clarified. Methods: We performed a retrospective, real-world study of all patients with advanced, resectable cutaneous or mucosal melanoma stage III/IV who received neoadjuvant treatment at the Department of Dermatology, University Hospital Zurich, Switzerland between April 2023 and September 2025. Primary endpoints were pathologic and radiologic response, EFS, recurrence-free survival (RFS), and safety. Results: In total, 31 patients were analyzed (52% female; median age 65 years), including 5 patients without lymph node involvement. Eighteen patients (58%) with cutaneous melanoma received neoadjuvant immunotherapy according to the NADINA protocol, three patients (10%) with mucosal melanoma received ipilimumab (1 mg/kg) and nivolumab (3 mg/kg), and ten patients (32%) were treated according to the SWOG S1801 protocol. A major pathologic response (MPR) was achieved in 12 of 31 patients (38%) overall, including 5 of 18 (28%) in the NADINA cohort, 6 of 10 (60%) in the SWOG S1801 cohort, and 1 of 3 (33%) in the mucosal cohort. We observed a pathologic partial response (pPR) in 7 of 31 patients (23%) overall, including 6 of 18 (33%) in the NADINA cohort and 1 of 3 (33%) in the mucosal cohort. A pathologic non-response (pNR) was seen in 9 of 31 patients (29%) overall, including 5 of 18 (28%) in the NADINA cohort, 3 of 10 (30%) in the SWOG S1801 cohort, and 1 of 3 (33%) in the mucosal cohort. Among all patients without lymph node involvement, 1 of 5 achieved MPR (20%), 2 had pPR (40%), and 2 showed pNR (40%). At data cutoff (median follow-up, 9.2 months), the 9-month EFS was 77% in the NADINA cohort, 74% in the SWOG S1801 cohort, and 33% in the mucosal cohort. In the whole cohort, 6-month RFS for the subgroups of MPR, pPR and pNR was 72.9%, 85.7% and 72.9%. Radiologic response evaluation with FDG-PET/CT after neoadjuvant therapy correlated significantly with pathologic response (p = 0.02). No patient with complete metabolic response (CMR) or partial metabolic response (PMR) recurred until data cutoff. In total, 6 of 31 patients (19%) showed stable metabolic disease (SMD), and 8 of 31 patients (26%) showed progressive metabolic disease (PMD). The 6-month RFS in the subgroups of SMD and PMD was 62.5% in each case. Adverse events (AEs) of grade 3 or higher were reported in 13 of 31 patients (42%) in the total real-world cohort, 8 of 18 in the NADINA cohort (44%), 2 of 10 (20%) in the SWOG S1801 cohort (20%), and 3 of 3 (100%) in the mucosal cohort. The most frequent grade 3/4 toxicities were immune-related (ir) Colitis (n = 3, 10%), irHepatitis (n = 2, 6%) and irMyocarditis (n = 2, 6%). Conclusions: Neoadjuvant immunotherapy is effective in real-world practice with a similar safety profile as shown in the clinical studies. Nevertheless, MPR rates in the NADINA real-world cohort were lower compared to the phase III trial. Larger multicenter studies are needed to validate our findings and to better understand response patterns, even in patients without lymph node involvement and in rare melanoma subtypes.

Vaginal mucosal melanoma is rare and insidious. A 74-year-old woman underwent 18F-FDG and 68Ga-FAPI-04 PET/CT for vaginal masses. The masses showed significant uptake of 68Ga-FAPI compared with 18F-FDG. In our case, this indicates the potential value of 68Ga-FAPI-04 PET/CT in the diagnosis of mucosal melanoma.

Primary head and neck mucosal melanoma is a rare and aggressive malignancy distinct from cutaneous melanoma, with no known association with UV exposure and a poorly understood pathogenesis. Diagnosis is often challenging due to its morphologic diversity and potential overlap with other malignancies. A subset of mucosal melanomas has been reported to express neuroendocrine markers, but data remain limited. We analyzed 19 specimens of head and neck mucosal melanoma, assessing morphology and immunoprofile with melanocytic markers, including SOX10, S100, HMB-45, Melan-A, and the neuroendocrine markers synaptophysin, chromogranin, and INSM1. While 4 specimens exhibited synaptophysin positivity, none were positive for all 3 neuroendocrine markers, and only 1 specimen stained for INSM1. The absence of chromogranin suggests that synaptophysin expression may be aberrant rather than indicative of true neuroendocrine differentiation. As a result, the use of synaptophysin alone should be discouraged, and more specific markers such as chromogranin and INSM1 should be used in conjunction. A broad immunohistochemical panel and a high index of suspicion are essential to avoid misclassification of head and neck mucosal melanomas.

Melanomagenesis involves genetic alterations affecting multiple oncogenic pathways, with BRAF and NRAS mutations representing frequently studied drivers. Recent evidence suggests melanoma development encompasses a broader spectrum including KIT mutations and novel variants exhibiting population-specific patterns. This study aimed to characterize the genetic landscape of melanomagenesis by analyzing BRAF, NRAS, KIT and novel mutations across melanoma subtypes in a Turkish cohort. Sixty-six genetic materials from 55 melanoma patients (2000-2016) were analyzed using targeted next-generation sequencing of 17 melanoma-relevant genes. Mutation profiling characterized genetic diversity across histological subtypes, with associations between molecular alterations and clinicopathological parameters evaluated using Fisher's exact test and Kruskal-Wallis test. Significant genetic diversity was observed, with 60% of cases harboring mutations. Analysis identified 22 wild-type cases, 13 BRAF mutations (23.6%), 4 NRAS mutations (7.3%), 6 KIT mutations (10.9%), and various alterations in TP53, KNSTRN, KRAS, PIK3CA, CDKN2A, OXA1L, and RAC1. Multiple concurrent mutations occurred in 5 cases (9.1%). Notably, BRAF mutation patterns differed substantially from Western populations: complete absence in superficial spreading melanomas (0.0% versus 50-70% in Caucasian cohorts) with enrichment in nodular melanomas (36.4%). KIT mutations showed significant enrichment in mucosal melanomas (33.3%, P = 0.003). A novel OXA1L frameshift mutation (p.A54Sfs*100) was identified. Melanomagenesis in the Turkish population demonstrates substantial genetic diversity with population-specific mutation patterns that diverge from Western paradigms. The absence of BRAF mutations in superficial spreading melanomas suggests distinct genetic pathways potentially related to different UV exposure patterns, genetic susceptibility, or gene-environment interactions. These findings have important implications for precision medicine, as therapeutic strategies developed in Western populations may require adaptation for diverse ethnic groups. Comprehensive genomic profiling including NF1 in larger multi-institutional cohorts is needed to fully characterize population-specific melanomagenesis mechanisms.

Oral melanocytic neoplasms, such as oral melanocytic nevi (OMN), oral dysplastic nevi (ODN), atypical melanocytic proliferation (AMP), and oral mucosal melanoma (OMM), represent < 1% of oral lesions. They are composed of pigment-producing cells with distinct biological behaviors. This study aimed to summarize the clinicopathological and molecular features of these lesions. Studies published in English (1950-2025) were retrieved from the PubMed database and Web of Science Core Collection. All articles presenting clinicopathological and molecular outcomes of OMN, ODN, AMP, and OMM were included. A narrative summary was created to describe the findings. OMN and OMM are well-described from a clinicopathological perspective. However, ODN and AMP remain scarcely documented. The genetic landscape of OMN suggests a limited role for driver mutations in BRAF or GNAQ, which promote the proliferation of pigmented-producing cells, often insufficient for malignancy. OMM exhibits a distinct molecular profile characterized by a scarcity of MAPK mutations and numerous copy-number changes, as well as amplifications and chromosomal rearrangements. In contrast, no genetic data are available for ODN and AMP. Oral melanocytic neoplasms are rare and have distinct clinicopathological features. Despite this, a gap exists in molecular data regarding ODN and AMP. Conversely, OMN and OMM have distinct profiles; in particular, the latter may benefit modestly from tyrosine kinase inhibitor treatment, as KIT and BRAF mutations are sensitive to imatinib and vemurafenib, respectively.

Background. Metastatic and unresectable melanoma is considered as one of the most aggressive oncological diseases with a high mortality rate. In Russia, two first line immunotherapy combinations have been approved: nivolumab plus ipilimumab (NIVO+IPI) and prolgolimab plus nurulimab (PROLGO+NURU). Both regimens use dual immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). However, the lack of direct randomized comparisons between these regimens makes it difficult to choose the optimal first-line therapy. Aim. This analysis evaluated the relative efficacy and safety of PROLGO+NURU versus NIVO 1 mg/kg + IPI 3 mg/kg (NIVO 1 + IPI 3) and NIVO 3 mg/kg + IPI 1 mg/kg (NIVO 3 + IPI 1) in patients with metastatic and unresectable melanoma using matching-adjusted indirect comparisons (MAICs). Materials and methods. A systematic literature review was performed in Embase and PubMed databases. Three phase III randomized controlled trials (RCTs) were included: OCTAVA (PROLGO+NURU, n=135), CheckMate 067 (NIVO 1 mg/kg + IPI 3 mg/kg, n=314), and CheckMate 511 (two regimens: NIVO 1 mg/kg + IPI 3 mg/kg, n=178; NIVO 3 mg/kg + IPI 1 mg/kg, n=180). Individual patient data (IPD) on outcomes and baseline characteristics for PROLGO+NURU were obtained from the OCTAVA trial. For the NIVO + IPI arms, IPD on overall survival (OS) and progression-free survival (PFS) were reconstructed using Guyot’s algorithm from the published Kaplan–Meier curves, and aggregated baseline-characteristic data were extracted. Pairwise unanchored MAICs were performed, weighting on key prognostic factors and effect modifiers: baseline lactate dehydrogenase levels, TNM-defined presence of distant metastasis (M-stage), Eastern Cooperative Oncology Group (ECOG) performance status, BRAF-mutation status, PD-L1 expression 5%, age, and sum of longest diameters of target lesions. To address partial population non-overlap – specifically, the absence of mucosal melanoma and of asymptomatic central-nervous-system metastases (after local control) in OCTAVA – a simulation-based modelling was applied. Efficacy outcomes were analyzed with Cox proportional-hazards regression, and safety outcomes with logistic regression. Results. OS was statistically significantly higher in the PROLGO+NURU arm than in either NIVO 1 + IPI 3 or NIVO 3 + IPI 1 arms: hazard ratio (HR) 0.69 (95% CI 0.47–0.96; p=0.026) in the CheckMate 067 population, HR 0.64 (0.42–0.91; p=0.011) and HR 0.63 (0.41–0.89; p=0.008) – in the CheckMate 511 population versus NIVO 1 + IPI 3 and NIVO 3 + IPI 1 regimens, respectively. Differences in PFS were statistically insignificant. The PROLGO+NURU regimen also demonstrated a more favorable safety profile, with a lower incidence of treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. Conclusion. MAICs results showed that the PROLGO+NURU regimen achieved statistically significant superiority in OS compared with the approved NIVO+IPI regimens in Russia (as of 2025). The PROLGO+NURU combination also displayed a more favorable safety profile, with fewer treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. It should be emphasized that the comparison is indirect and the horizon of the comparison was limited (by about 50 months in CheckMate 511 population and 65 months in CheckMate 067 population). Consequently, the findings should be interpreted cautiously. Further updates incorporating data for the longer follow-up, including real-world data, are recommended.

To evaluate clinical outcomes and quality of life (QOL) following hypofractionated spot-scanning proton therapy (SSPT) for head and neck malignant mucosal melanoma (HNMM). This retrospective study included 39 patients treated with SSPT (60-64 Gy[RBE] in 15-16 fractions) between 2013 and 2023. Endpoints included overall survival (OS), local control (LC), progression-free survival (PFS), toxicities, and QOL. Most tumors were located in the sinonasal cavity (n = 32). Surgery was performed in 8 patients; 19 received immune checkpoint inhibitors post-SSPT. The 3-year OS, LC, and PFS were 50%, 83%, and 30%, respectively. Larger tumor volumes (≥ 20 cm3) were linked to worse PFS. Grade 3 mucositis occurred in 13%. Late toxicities included sinus disorder, osteonecrosis, and blindness (3%-5%). QOL was largely preserved, with notable declines in pain, swallowing, and mouth opening. SSPT provides favorable LC with acceptable toxicity. Effective systemic therapies are needed to improve long-term outcomes.

Abstract Introduction : Vaginal melanomas account for less than 3% of vaginal neoplasms and are characterized by poor prognosis. Case report : We present the case of a 65-year-old patient with a history of invasive breast carcinoma and BRAF-negative vaginal melanoma, showing positive immunostaining for S100, SOX-10, PRAME, and vimentin, who was referred to the Dermatology Clinic of Mureș County Clinical Hospital for an erysipelas-like skin reaction on the upper limb affected by chronic lymphedema secondary to axillary lymph-adenectomy. Clinical examination revealed diffuse melanosis cutis, acanthosis nigricans, and tripe palms. The patient also exhibited stigmata of Cushing syndrome, with a recent history of systemic corticosteroid therapy. Dermoscopy was performed and revealed dark brown, well defined, round macules on the genital mucosa, while the vaginal mass exhibited dermoscopic signs suggestive of melanoma. Conclusions : Clinical examination and dermoscopy are essential for patients with mucosal melanomas, as they can uncover details that are critical for creating a comprehensive picture.

Therapeutic Value of 18F-FDG PET/CT in Monitoring Cutaneous and Mucosal Melanoma: Preliminary Experience from Sousse

CO175 Overall Treatment Landscape of Mucosal Melanoma